New PBS cancer listings
The checkpoint inhibitor pembrolizumab (Keytruda, MSD), already PBS-listed for metastatic melanoma, will also be subsidised for patients with relapsed or refractory Hodgkin lymphoma.
It’s one of two drugs for cancer indications to be listed from 1 May, federal health minister Greg Hunt announced.
To qualify for pembrolizumab, the patient must have relapsed or refractory disease after having an autologous stem cell transplant.
Those judged unsuitable for an autologous transplant and refractory after trying at least two treatments are also eligible.
Mr Hunt estimated that 120 patients